Lazard Asset Management LLC Pacira Bio Sciences, Inc. Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$30.68 - $40.09 $31,600 - $41,292	1,030 New	1,030 $31,000
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $54,858 - $66,978	1,544 New	1,544 $63,000
Q2 2022 Aug 09, 2022	SELL	$51.49 - $81.64 $168,990 - $267,942	-3,282 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$60.03 - $76.49 $39,139 - $49,871	-652 Reduced 16.57%	3,282 $250,000
Q4 2021 Feb 09, 2022	BUY	$47.97 - $62.21 $188,713 - $244,734	3,934 New	3,934 $236,000
Q3 2020 Nov 13, 2020	SELL	$51.97 - $63.0 $189,430 - $229,635	-3,645 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$30.8 - $52.47 $16,108 - $27,441	-523 Reduced 12.55%	3,645 $191,000
Q1 2020 May 14, 2020	BUY	$28.4 - $50.7 $95,168 - $169,895	3,351 Added 410.16%	4,168 $139,000
Q4 2019 Feb 13, 2020	SELL	$36.31 - $46.83 $103,628 - $133,652	-2,854 Reduced 77.74%	817 $37,000
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $130,907 - $165,158	3,671 New	3,671 $139,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.